eigerbioadmin

Home»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 70 blog entries.
17 05, 2017

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema

2017-05-17T13:43:24+00:00

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema - Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema PALO ALTO, Calif., May 17, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies of ubenimex in [...]

15 05, 2017

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

2017-05-15T14:39:47+00:00

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension - Phase 2 LIBERTY Data Expected First Quarter 2018 PALO ALTO, Calif., May 15, 2017 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of [...]

12 05, 2017

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results

2017-05-12T12:53:17+00:00

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results — Five Phase 2 Programs in Four Orphan Indications Progressing — Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif., May 12, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the [...]

8 05, 2017

Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago

2017-05-15T14:42:05+00:00

Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago PALO ALTO, Calif., May 8, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis presented at Digestive Disease Week (DDW) in [...]

4 05, 2017

Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City

2017-05-15T14:42:12+00:00

Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City - Phase 2 LIBERTY Study Update for Ubenimex in PAH PALO ALTO, Calif. – May 4, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development [...]

3 05, 2017

Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection

2017-05-15T14:42:19+00:00

Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection - LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling PALO ALTO, Calif., May 3, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the U.S. IND has been [...]

24 04, 2017

Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago

2017-05-15T14:42:26+00:00

Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago PALO ALTO, Calif., April 24, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that an abstract describing prevalence of hepatitis delta virus (HDV) in the U.S. will be presented at Digestive Disease Week (DDW) in Chicago, Illinois, May 6 to 9, 2017. Accepted [...]

21 04, 2017

Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017

2017-05-15T14:42:31+00:00

Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017 PALO ALTO, Calif., April 21, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional supportive and encouraging lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The International Liver Congress™ 2017, [...]

18 04, 2017

Eiger Announces Industry Veteran Lisa Porter, MD to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia – Novel Liquid Formulation of Exendin 9-39 Advancing

2017-05-15T14:42:40+00:00

Eiger Announces Industry Veteran Lisa Porter, MD to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia   - Novel Liquid Formulation of Exendin 9-39 Advancing    PALO ALTO, Calif., April 18, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the [...]

6 04, 2017

Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting

2017-05-15T14:42:49+00:00

Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting PALO ALTO, Calif., April 6, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at the European [...]